Neutral sphingomyelinase 2: A promising drug target for CNS disease
2024 · Advances in pharmacology · 4 citations
https://doi.org/10.1016/bs.apha.2024.10.015
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
2
Papers
6
Citations
2
h-index
0
i10-index
Matthew Stremlau is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Autophagy in Disease and Therapy & Sphingolipid Metabolism and Signaling & Health and Medical Research Impacts. The author has an h-index of 2, co-authored 2 publications.
Click to start Chat